Incubating the Next Generation of Health AI.
PredxBio
Founded in 2017, PredxBio is a Pittsburgh-based techbio company harnessing the power of spatial biology to unravel the hidden circuitry of the tumor microenvironment. The company employs proprietary artificial intelligence (AI) technologies to analyze whole-slide images through spatial analytics. Its platform predicts how patients will respond to immunotherapy and aims to accelerate drug development and clinical trials for biopharmaceutical partners. PredxBio is the fourth startup founded by Michael J. Becich, MD, PhD, professor of biomedical informatics, who previously focused on whole-slide imaging and digital pathology in his earlier ventures. Dr. Becich cofounded PredxBio alongside Chakra Chennubhotla, Ph.D., Lansing Taylor, Ph.D., and Jeffrey L. Fine, M.D.
DeepRx
Precision oncology is the focus of DeepRx, an AI startup that develops clinical decision support systems. The company specializes in creating AI methods that predict drug efficacy and sensitivity based on individual patient profiles. This includes treatments such as chemotherapies, molecularly targeted drugs, and immunotherapies. DeepRx's lead product, COLOXIS, is an AI-powered tool designed to optimize drug selection for patients with colorectal cancer. The chief science officer, Xinghua Lu, MD, PhD, professor of biomedical informatics, brings two decades of research experience in AI and medicine to the company's scientific direction. He co-founded DeepRx in 2019 with Gregory F. Cooper, MD, PhD, professor emeritus of biomedical informatics, and Lujia Chen, PhD, assistant professor of biomedical informatics.
READE.ai
Detecting brain ischemia in real time is the mission of READE.ai, a Pittsburgh-based startup focused on evaluating adverse events during surgery. The company addresses a critical need for intraoperative brain monitoring in the approximately 3.5 million surgeries performed nationwide that have a heightened risk of brain ischemia. If these events are not detected, they can lead to serious consequences such as stroke or death. The chief science officer of READE is Shyam Vsweswaran, MD, PhD, a professor of biomedical informatics. He cofounded the company in 2021 with Parthasarathy Thirumala, MD, a professor of neurosurgery and the director of the Center for Clinical Neurophysiology; Kayhan Batmanghelich, PhD, an assistant professor in the Department of Electrical and Computer Engineering at Boston University; and Jessi Espino, MD, MS, a senior research scientist in biomedical informatics.
ThetaRho
Simplifying healthcare administration through AI is the driving purpose behind ThetaRho, a healthcare AI company located in San Jose, California, cofounded by Kannan Govindarajan, PhD, and Ramani Narayan in 2023. The company's mission is to transform health care by simplifying administrative processes, empowering providers with streamlined access to critical patient data, improving care delivery and enhancing patient outcomes. ThetaRho offers a natural language interface that uses AI and data to retrieve relevant patient information at the point of care within the electronic health record. Shyam Visweswaran, MD, PhD, serves as the chief medical officer, playing a crucial role in product development, design, data management, and ontology development.
